UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.)

Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**

☐ Definitive Proxy Statement

☒ Definitive Additional Materials

☐ Soliciting Material Pursuant to Section 240.14a-12

JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

☒ No fee required.

☐ Fee paid previously with preliminary materials

☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

July 2022

2022 Annual General Meeting

Innovating to Transform the Lives of Patients and Their Families

Jazz Pharmaceuticals

Transforming Lives. Redefining

Caution Concerning Forward-Looking Statements

This presentation contains forward-looking statements and financial targets, including, but not limited to, statements related to: t
operating guidance and the Company's expectations related thereto; the Company's expectation of sustainable growth and enh
Company's anticipated investing in its pipeline of novel therapies, and delivering innovative therapies for patients; the Company
commercial potential of its products, including the blockbuster potential of Epidiolex; planned or anticipated clinical trial events, i
confirming clinical benefit or enabling regulatory submissions; planned or anticipated regulatory submissions and filings, includir
statements that are not historical facts. These forward-looking statements are based on the Company's current plans, objectives
could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, whi
oxybate products, Zepzelca and other key marketed products; effectively launching and commercializing the Company's other p
time-consuming and uncertain regulatory approval process, including the risk that the Company's current and/or planned regula
the risk that the Company's sBLAs seeking approval for a revised dosing and administration label for Rylaze may not be approv
clinical success, including risks related to failure or delays in successfully initiating or completing clinical trials and assessing pat
COVID-19 pandemic; the Company's failure to realize the expected benefits of its acquisition of GW Pharmaceuticals as rapidly
risk that the legacy GW Pharmaceuticals business will not be integrated successfully or that such integration may be more diffic
economic, financial, and healthcare system disruptions and the current and potential future negative impacts to the Company's
Company's intellectual property rights and the Company's commercial success being dependent upon the Company obtaining,
manufacture of the Company's products and product candidates; complying with applicable U.S. and non-U.S. regulatory requir
investigations, legal proceedings and other actions; identifying and acquiring, in-licensing or developing additional products or p
Company's ability to realize the anticipated benefits of its collaborations and license agreements with third parties; the sufficienc
the Company's ability to achieve expected future financial performance and results and the uncertainty of future tax, accounting
uncertainty of future tax and other provisions and estimates; the Company's ability to meet its projected long-term goals and obj
significant judgments and assumptions underlying the Company's long-term goals and objectives; and other risks and uncertain
Pharmaceuticals' Securities and Exchange Commission filings and reports, including the Company's Annual Report on Form 10
Company is not currently aware may also affect the Company's forward-looking statements and may cause actual results and th

This presentation contains long-term and other financial targets of the Company relating to Vision 2025, including with respect t
these financial targets were prepared in good faith, no assurance can be made regarding future results or events. These financi
achieving deleveraging and diversification targets for 2022 that were set and communicated in 2021; management's assumptior
Products) and generic versions of sodium oxybate and the level of AG Product royalties to the Company, the safety and efficacy
estimates of the size of the eligible patient populations that may ultimately be served by Epidiolex/Epidyolex, new patient marke
duration of therapy, and the safety and efficacy profiles of therapies competing with the Company's oncology products; and the
contribution from growth opportunities related to pipeline development and potential corporate development opportunities that m
judgments with respect to, among other things, future economic, competitive, regulatory, market and financial conditions, as wel
realized, and that are inherently subject to significant business, economic, competitive and regulatory risks and uncertainties, in
biotechnology industry generally, all of which are difficult to predict and many of which are outside the control of the Company. T
realized and the Company's actual results may differ materially from those reflected in these financial targets. In addition, these
relied upon as being necessarily indicative of future results, and investors are otherwise cautioned not to place undue reliance o
the accuracy and completeness of industry and market information from public sources or provided to the Company by third par

Jazz Ph

Our P

is to **innovate** to **tr**
patients and

Who W

We are focused on de
medicines for people wit
with limited or no therape
live their liv

By transforming biopharm
novel medicines, we a
around the world the opp
possible – **to make the**



Casey
Xywav IH Patient

ALL = acute lymphoblastic leukemia, IH = idiopathic hypersomnia

Track Record of Strong Execution

STRONG COMMERCIAL FRANCHISES

5 key product launches

in 2020 - 2021

Leading neuroscience franchises

xywav™

Epidiolex® (cannabidiol)

Substantial revenue diversification

EXPANDE CAPABILIT

xyw

Indication ex
supported by **rol**

RYLA

Phase 1 initia
~2.5

STRATEGIC CAPITAL ALLOCATIO

>$3 billion in revenue in 2021

Expect 60-65% c sales driven by

1. Products launched or acquired since 2019.

2L = second-line, IH = idiopathic hypersomnia, SCLC = small cell lung cancer

Vision 2025: Deliver Sustainable

COMMERCIAL

Substantial **revenue** target for 2025

PIPELINE

Pipeline poter
multiple nc
appr
by end of

Corporate development progress anticipated to
sharpen strategic focus, optimize portfolio and
growth and sha

Vision 2025 represents Jazz estimates of future performance

Track Record of Revenue Growt

Grace
Epidiolex Patient

GUIDED BY OUR
PATIENT-CENTRI

2005 – 2021:
YoY revenue growt
16 consecutive ye

2016 – 2021:
16% CAGR

Revenue $ in millio

CAGR = compound annual growth rate.

Consistently Enhancing our ESG

Integrating our Approach to ESG



We are committed to advancing our ESG S
report against the upcoming International
senior management, and CSSI (Corporate
and Pharmaceutical ESG standards that ap
and in alignment with many of the U.N.'s Su



Jazz Pharmace

Commitment to align with UN SD
ISSB reporting through the anti
publication of our first corporate
responsibility (CSR) report in

UN SDGs = United Nations Sustainable Development Goals
SASB = Sustainability Accounting Standards Board

2022 Annual General Meeting

Agenda and Overview of Proposal 4

Proposal 1	Election of Directors
Proposal 2	Auditor Appointment and Remuneration
Proposal 3	"Say-on-Pay"
Proposal 4	Authority to Issue Shares for Cash Without First Offering Shares to Existing Shareholders (see slides 9-11)
Proposal 5	Meeting Adjournment

Responding to Shareholder Fee

OUR PROPOSED AUTHORITY AT THE 2022 AGM IS MEA
AT THE 2021 AGM WHILE PROVIDING US WITH A L
STRATEGY

Shareholder Engagement

- We engaged extensively on our pre-emption opt-out authority prior to and following the 2021 AGM
- Feedback received indicated that certain shareholders preferred:
  - Limits on the amount of shares that could be issued without shareholder pre-emptive rights
  - Limit on the authority duration to less than 5 years

How does the 2022 AGM Propos
Proposal



Why our Shareholders should ap

1. **Supports Vision 2025's Delivery of *Sustainable Growth* and *Enhanced Value***

2. **During our more than ten years as an Irish-incorporated company, we have demonstrated *disciplined use of equity* in furtherance of our strategy for growth**

3. **Vital *flexibility* for how we intend *to advance our business***